Authors: W Kromdijk M A Sikma M P H van den Broek J H Beijnen A D R Huitema D W de Lange
Publish Date: 2013/02/27
Volume: 39, Issue: 5, Pages: 977-978
Abstract
Patients infected with the 2009 H1N1 pandemic influenza virus often develop severe viral pneumonia with acute respiratory distress syndrome ARDS and multiple organ failure Highdose oseltamivir ≥150 mg twice daily has been advocated as optimal treatment 1 However the scientific evidence for this advice is lacking thus far 2 Therefore we explored the pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate in critically ill patients with H1N1 pandemic influenza following different dosing regimensAll patients with H1N1 pandemic influenza admitted to the ICU of the University Medical Center Utrecht were eligible for inclusion Patients received oseltamivir at a dose determined by their treating physician and blood samples were drawn at t = 0 1 2 3 4 and 8 h on day three of treatment Oseltamivir and oseltamivir carboxylate plasma concentrations were determined by HPLC–MS/MS 3 The area under the concentration–time curve from 0
Keywords: